PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations.
Michael V HolmesChristiana KartsonakiRuth BoxallKuang LinNicola ReeveCanqing YuJun LvDerrick A BennettMichael R HillLing YangYiping ChenHuaidong DuIain TurnbullRory CollinsRobert J ClarkeMartin D TobinLiming LiIona Y MillwoodZhengming ChenRobin G Waltersnull nullPublished in: European journal of preventive cardiology (2024)
LDL-C-lowering PCSK9 genetic variants are associated with lower risk of subclinical and clinical atherosclerotic vascular disease, but higher risks of respiratory diseases. Pharmacovigilance studies may be required to monitor patients treated with therapeutic PCSK9 inhibitors for exacerbations of respiratory diseases or respiratory tract infections.